Lv3
264 积分 2024-08-07 加入
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
9天前
已完结
Beyond PARP—POLθ as an anticancer target
9天前
已完结
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma
18天前
已完结
Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy
1个月前
已完结
On the relationship between hERG inhibition and the magnitude of QTc prolongation: An in vitro to clinical translational analysis
1个月前
已完结
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
1个月前
已完结
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
1个月前
已关闭
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
1个月前
已完结
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
2个月前
已关闭
Genetic determinants of cellular addiction to DNA polymerase theta
2个月前
已完结
皖公网安备34019202002308
